Baron Wealth Management LLC Purchases 1,381 Shares of Haleon plc (NYSE:HLN)

Baron Wealth Management LLC increased its position in Haleon plc (NYSE:HLN) by 4.3% during the fourth quarter, Holdings Channel reports. The firm owned 33,632 shares of the company’s stock after buying an additional 1,381 shares during the quarter. Baron Wealth Management LLC’s holdings in Haleon were worth $321,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Fortitude Family Office LLC bought a new stake in Haleon in the 3rd quarter valued at $28,000. Versant Capital Management Inc lifted its stake in shares of Haleon by 2,029.1% during the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after buying an additional 3,348 shares during the last quarter. Geneos Wealth Management Inc. bought a new position in Haleon in the 4th quarter valued at about $35,000. Toronto Dominion Bank lifted its position in Haleon by 3,470.0% during the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after acquiring an additional 3,470 shares during the last quarter. Finally, Prospera Private Wealth LLC bought a new stake in shares of Haleon during the third quarter worth approximately $57,000. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Trading Down 0.2 %

Shares of Haleon stock opened at $9.53 on Thursday. The firm’s 50-day moving average price is $9.54 and its two-hundred day moving average price is $9.75. The company has a market capitalization of $43.12 billion, a price-to-earnings ratio of 28.01, a PEG ratio of 2.60 and a beta of 0.29. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80.

Haleon (NYSE:HLN) last announced its quarterly earnings data on Thursday, October 31st. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The business had revenue of $3.62 billion for the quarter, compared to analysts’ expectations of $3.74 billion. During the same period last year, the firm posted $0.10 earnings per share. On average, analysts forecast that Haleon plc will post 0.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HLN has been the subject of a number of recent research reports. Sanford C. Bernstein cut shares of Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.